JP2015510891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510891A5 JP2015510891A5 JP2015500596A JP2015500596A JP2015510891A5 JP 2015510891 A5 JP2015510891 A5 JP 2015510891A5 JP 2015500596 A JP2015500596 A JP 2015500596A JP 2015500596 A JP2015500596 A JP 2015500596A JP 2015510891 A5 JP2015510891 A5 JP 2015510891A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- neck
- head
- cell carcinoma
- squamous cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 20
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 20
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 13
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 13
- 102000038030 PI3Ks Human genes 0.000 claims 12
- 108091007960 PI3Ks Proteins 0.000 claims 12
- 230000037361 pathway Effects 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012472 biological sample Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 claims 8
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 claims 8
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 claims 7
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 claims 7
- GMYLVKUGJMYTFB-UHFFFAOYSA-N 5-ethyl-3-[2-methyl-6-(1h-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C(C(=N1)C)=CC=C1C1=NN=CN1 GMYLVKUGJMYTFB-UHFFFAOYSA-N 0.000 claims 6
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 6
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 230000002018 overexpression Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- -1 2-methyl-6- (1H-1,2,4-triazol-3-yl) pyridin-3-yl Chemical group 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 3
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000027405 negative regulation of phosphorylation Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611361P | 2012-03-15 | 2012-03-15 | |
| US61/611,361 | 2012-03-15 | ||
| US201261715323P | 2012-10-18 | 2012-10-18 | |
| US61/715,323 | 2012-10-18 | ||
| PCT/US2013/031206 WO2013138557A1 (en) | 2012-03-15 | 2013-03-14 | Treatment of cancer with tor kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038434A Division JP2019108368A (ja) | 2012-03-15 | 2019-03-04 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015510891A JP2015510891A (ja) | 2015-04-13 |
| JP2015510891A5 true JP2015510891A5 (enExample) | 2016-03-31 |
Family
ID=48014336
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500596A Pending JP2015510891A (ja) | 2012-03-15 | 2013-03-14 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
| JP2019038434A Pending JP2019108368A (ja) | 2012-03-15 | 2019-03-04 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
| JP2021050188A Pending JP2021102637A (ja) | 2012-03-15 | 2021-03-24 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019038434A Pending JP2019108368A (ja) | 2012-03-15 | 2019-03-04 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
| JP2021050188A Pending JP2021102637A (ja) | 2012-03-15 | 2021-03-24 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130245026A1 (enExample) |
| EP (1) | EP2825170B1 (enExample) |
| JP (3) | JP2015510891A (enExample) |
| KR (3) | KR20210071101A (enExample) |
| CN (2) | CN108992446A (enExample) |
| AU (1) | AU2013203153B2 (enExample) |
| BR (1) | BR112014022703A2 (enExample) |
| CA (1) | CA2866872A1 (enExample) |
| EA (1) | EA028414B1 (enExample) |
| ES (1) | ES2677874T3 (enExample) |
| IL (1) | IL234602B (enExample) |
| MX (1) | MX360878B (enExample) |
| MY (1) | MY174022A (enExample) |
| NI (1) | NI201400111A (enExample) |
| NZ (1) | NZ628416A (enExample) |
| PH (1) | PH12014502029A1 (enExample) |
| SG (1) | SG11201405707XA (enExample) |
| TW (1) | TWI583385B (enExample) |
| UA (1) | UA114315C2 (enExample) |
| WO (1) | WO2013138557A1 (enExample) |
| ZA (1) | ZA201406706B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201405707XA (en) * | 2012-03-15 | 2014-10-30 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9346812B2 (en) | 2013-01-16 | 2016-05-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| HK1221150A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用二氢吡嗪并-吡嗪类对癌症的治疗 |
| BR112015026257B1 (pt) | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
| JP6382945B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| EP2986321A1 (en) * | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| CN105339008A (zh) | 2013-04-17 | 2016-02-17 | 西格诺药品有限公司 | 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法 |
| MX393164B (es) | 2013-04-17 | 2025-03-21 | Signal Pharm Llc | Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona. |
| JP2016522177A (ja) * | 2013-04-17 | 2016-07-28 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160868A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| AU2015289929A1 (en) | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009004019A (es) * | 2006-10-19 | 2009-06-19 | Signal Pharm Llc | Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa. |
| NZ576278A (en) | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| EP2320894B1 (en) * | 2008-08-20 | 2016-12-28 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Chemoprevention of head and neck squamous cell carcinomas |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| KR20120091240A (ko) | 2009-10-26 | 2012-08-17 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물의 합성 및 정제 방법 |
| US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
| SG11201405707XA (en) * | 2012-03-15 | 2014-10-30 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
-
2013
- 2013-03-14 SG SG11201405707XA patent/SG11201405707XA/en unknown
- 2013-03-14 US US13/803,061 patent/US20130245026A1/en not_active Abandoned
- 2013-03-14 MX MX2014011077A patent/MX360878B/es active IP Right Grant
- 2013-03-14 NZ NZ628416A patent/NZ628416A/en not_active IP Right Cessation
- 2013-03-14 KR KR1020217017407A patent/KR20210071101A/ko not_active Ceased
- 2013-03-14 EP EP13713006.8A patent/EP2825170B1/en active Active
- 2013-03-14 CA CA2866872A patent/CA2866872A1/en not_active Abandoned
- 2013-03-14 KR KR1020207016306A patent/KR20200070416A/ko not_active Ceased
- 2013-03-14 BR BR112014022703-9A patent/BR112014022703A2/pt not_active IP Right Cessation
- 2013-03-14 ES ES13713006.8T patent/ES2677874T3/es active Active
- 2013-03-14 KR KR1020147028707A patent/KR102122617B1/ko active Active
- 2013-03-14 WO PCT/US2013/031206 patent/WO2013138557A1/en not_active Ceased
- 2013-03-14 CN CN201811057528.7A patent/CN108992446A/zh active Pending
- 2013-03-14 CN CN201380024859.XA patent/CN104519885A/zh active Pending
- 2013-03-14 UA UAA201411218A patent/UA114315C2/uk unknown
- 2013-03-14 EA EA201491699A patent/EA028414B1/ru not_active IP Right Cessation
- 2013-03-14 TW TW102109160A patent/TWI583385B/zh active
- 2013-03-14 AU AU2013203153A patent/AU2013203153B2/en not_active Ceased
- 2013-03-14 JP JP2015500596A patent/JP2015510891A/ja active Pending
- 2013-03-14 MY MYPI2014702568A patent/MY174022A/en unknown
-
2014
- 2014-09-11 IL IL234602A patent/IL234602B/en active IP Right Grant
- 2014-09-12 NI NI201400111A patent/NI201400111A/es unknown
- 2014-09-12 ZA ZA2014/06706A patent/ZA201406706B/en unknown
- 2014-09-12 PH PH12014502029A patent/PH12014502029A1/en unknown
-
2019
- 2019-03-04 JP JP2019038434A patent/JP2019108368A/ja active Pending
-
2021
- 2021-03-24 JP JP2021050188A patent/JP2021102637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510891A5 (enExample) | ||
| JP2015511964A5 (enExample) | ||
| JP2015516375A5 (enExample) | ||
| JP2021102637A5 (enExample) | ||
| JP2015511963A5 (enExample) | ||
| JP2016516816A5 (enExample) | ||
| Costa et al. | Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review | |
| Fasolo et al. | Targeting mTOR pathways in human malignancies | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2020183413A (ja) | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 | |
| TN2011000626A1 (en) | 1h-imidazo[4,5-c]quinolinone derivatives | |
| WO2009007748A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| NO20063758L (no) | Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| JP2018515570A (ja) | Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４ | |
| MX2009008486A (es) | Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor. | |
| WO2009007751A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| JP2016518370A5 (enExample) | ||
| MX384930B (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer. | |
| TW202241440A (zh) | 預防或治療抗腫瘤劑相關疾病或病症的方法 | |
| NZ628416A (en) | Treatment of cancer with tor kinase inhibitors | |
| JP5878628B2 (ja) | ピリドナフチリジン型ＰＩ３ＫおよびｍＴＯＲ二重阻害薬ならびにその調製および使用 | |
| TW201217374A (en) | Pharmaceutical combinations | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения |